Previous close | 66.79 |
Open | 65.00 |
Bid | 65.52 x 200 |
Ask | 65.64 x 200 |
Day's range | 63.63 - 66.48 |
52-week range | 44.20 - 82.04 |
Volume | |
Avg. volume | 713,100 |
Market cap | 7.131B |
Beta (5Y monthly) | N/A |
PE ratio (TTM) | N/A |
EPS (TTM) | -4.14 |
Earnings date | 10 May 2024 - 15 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 103.29 |
-- VAX-31 Adult Phase 1/2 Study Enrollment Completed; Topline Safety, Tolerability and Immunogenicity Data Expected in Third Quarter of 2024 -- -- Following VAX-31 Adult Phase 1/2 Study Readout, Vaxcyte to Advance VAX-24 or VAX-31 to Adult Phase 3 Program -- -- VAX-24 Infant Phase 2 Study Enrollment Completed; Topline Data from Primary Immunization Series Expected by End of First Quarter of 2025, Followed by Topline Data from Booster Dose by End of 2025 -- -- $1.9 Billion in Cash, Cash Equivalen
On May 1, 2024, Jim Wassil, the Chief Operating Officer of Vaxcyte Inc (NASDAQ:PCVX), sold 3,000 shares of the company.
SAN CARLOS, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, announced today that Company management will participate in a fireside chat at the 23rd Annual Needham Virtual Healthcare Conference on Tuesday, April 9 at 12:45 p.m. ET / 9:45 a.m. PT. A live webcast of the fireside chat can be accessed through the Investors & Media se